Co-stimulation blockade targeting CD154 and CD28/B7 modulates the induced antibody response after a pig-to-baboon cardiac xenograft

Xenotransplantation

Volumn 12, Issue 3, 2005, Pages 197-208

  Wu, Guosheng ^a   Pfeiffer, Steffen ^a   Schröder, Carsten ^a   Zhang, Tianshu ^a   Nguyen, Bao N ^a   Lea, William ^b   Kelishadi, Sean ^a   Atkinson, James B ^b   Schuurman, Henk Jan ^c   White, David J G ^d   Azimzadeh, Agnes M ^a   Pierson III, Richard N ^a,e  

^a UNIVERSITY OF MARYLAND   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Immerge Biotherapeutics Inc   (United States)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

B7; CD154; CD28; CD40; Co stimulation; CTLA4; Delayed xenograft rejection; hDAF transgenic organs; ICOS; MCP transgenic organs; Nonhuman primates; T cell activation; Xenoantigen; Xenoreactive antibody; Xenotransplantation

Indexed keywords

CD20 ANTIBODY; CD28 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DECAY ACCELERATING FACTOR; GALACTOSYLGALACTOSE; GALACTOSYLGALACTOSE ANTIBODY; GAS 914; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IDEC 131; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEX 1285; RITUXIMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BABOON; BLOOD CLOTTING DISORDER; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; FLOW CYTOMETRY; GRAFT FAILURE; GRAFT SURVIVAL; HEART GRAFT; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; SWINE; T LYMPHOCYTE ACTIVATION;

ANEMIA; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES; ANTIBODY FORMATION; ANTIGENS, CD28; ANTIGENS, CD80; CD40 LIGAND; DISACCHARIDES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MALE; MYOCARDIUM; PAPIO; SWINE; THROMBOCYTOPENIA; TRANSPLANTATION, HETEROLOGOUS;

EID: 20244378379     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3089.2005.00221.x     Document Type: Article

References (42)

1. GALILI U, MACHER BA, BUEHLER J, SHOHET SB. Human natural anti-alpha-galactosyl IgG. II. The specific recognition of alpha (1,3)-linked galactose residues. J Exp Med 1985; 162: 573.
2. DALMASSO AP, VERCELLOTTI GM, FISCHEL RJ et al. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am J Pathol 1992; 140: 1157.
3. COOPER DK. Depletion of natural antibodies in non-human primates - a step towards successful discordant xenografting in humans. Clin Transplant 1992; 6: 178.
4. COZZI E, WHITE DJ. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1: 964.
5. DAI Y, VAUGHT TD, BOONE J et al. Targeted disruption of the alpha 1,3-galactosyltransferase gene in cloned pigs. Nat Biotechnol 2002; 20: 251.
6. KUWAKI K, TSENG YL, DOR FJ et al. Heart transplantation in baboons using a1,3-Galactosyl-transferase gene-knockout pigs as donors: initial experience. Nat Med 2005; 11: 29.
7. BACH FH, ROBSON SC, WINKLER H et al. Barriers to xenotransplantation. Nat Med 1995; 1: 869.
8. LIN SS, WEIDNER BC, BYRNE GW et al. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest 1998; 101: 1745.
9. BUHLER L, AWWAD M, BASKER M et al. High-dose porcine hematopoietic cell transplantation combined with CD40 ligand blockade in baboons prevents an induced anti-pig humoral response. Transplantation 2000; 69: 2296.
10. SCHMOECKEL M, BHATTI FN, ZAIDI A et al. Orthotopic heart transplantation in a transgenic pig-to-primate model. Transplantation 1998; 65: 1570.
11. ZAIDI A, SCHMOECKEL M, BHATTI F et al. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors. Transplantation 1998; 65: 1584.
12. BYRNE GW, SCHIRMER JM, FASS DN et al. Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. Am J Transplant 2005. doi: 10.1111/j.1600-6143.2005.00792.x
13. MCGREGOR CG, TEOTIA SS, BYRNE GW et al. Cardiac xenotransplantation: progress toward the clinic. Transplantation 2004; 78: 1569.
14. QUEZADA SA, JARVINEN LZ, LIND EF, NOELLE RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004; 22: 307.
15. LARSEN CP, ELWOOD ET, ALEXANDER DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
16. KIRK AD, HARLAN DM, ARMSTRONG NN et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997; 94: 8789.
17. KUWAKI K, KNOSALLA C, DOR FJ et al. Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human anti-human CD154 mAb-based regimen. Am J Transplant 2004; 4: 363.
18. BYRNE GW, MCCURRY KR, MARTIN MJ et al. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 1997; 63: 149.
19. STARK JH, SMITH JA, GRIDELI B. Sensitivity of baboon lymphoytes to cyclorsporine A and FK506: relative resistance of alloactivated cells to CsA. Transpl Int 1994; 7: 372.
20. SCHRODER C, AZIMZADEH AM, WU GS et al. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol 2003; 12: 19.
21. BYRNE GW, SCHWARZ A, FESI JR et al. Evaluation of different alpha-Galactosyl glycoconjugates for use in xenotransplantation. Bioconjug Chem 2002; 13: 571.
22. ZHONG R, LUO Y, YANG H et al. Improvement in human decay accelerating factor transgenic porcine kidney xenograft rejection with intravenous administration of gas914, a polymeric form of alphaGal. Transplantation 2003; 75: 10.
23. KATOPODIS AG, WARNER RG, DUTHALER RO et al. Removal of anti-Galalpha1,3Gal xenoantibodies with an injectable polymer. J Clin Invest 2002; 110: 1869.
24. AZIMZADEH A, WOLF P, THIBAUDEAU K et al. Comparative study of target antigens for primate xenoreactive natural antibodies in pig and rat endothelial cells. Transplantation 1997; 64: 1166.
25. COZZI E, VIAL C, OSTLIE D et al. Maintenance triple immunosuppression with cyclosporin A, mycophenolate sodium and steroids allows prolonged survival of primate recipients of hDAF porcine renal xenografts. Xenotransplantation 2003; 10: 300.
26. ZHANG JP, BLUM MG, CHANG AC et al. Immunohistologic evaluation of mechanisms mediating hyperacute lung rejection, and the effect of treatment with K76-COOH, FUT-175, and anti-Gal column immunoadsorption. Xenotransplantation 1999; 6: 249.
27. SACHS DH, SYKES M, ROBSON SC, COOPER DK. Xenotransplantation. Adv Immunol 2001; 79: 129.
28. SAADI S, HOLZKNECHT RA, PATTE CP, STERN DM, PLATT JL. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995; 182: 1807.
29. ROBSON SC, SCHULTE AM, ESCH J 2nd, BACH FH. Factors in xenograft rejection. Ann N Y Acad Sci 1999; 875: 261.
30. ELWOOD ET, LARSEN CP, CHO HR et al. Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade. Transplantation 1998; 65: 1422.
31. YAMADA K, YAZAWA K, SHIMIZU A et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha 1,3- galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 2005; 11: 32.
32. ZHU A. Binding of human natural antibodies to nonalphaGal xenoantigens on porcine erythrocytes. Transplantation 2000; 69: 2422.
33. BUHLER L, XU Y, LI W, ZHU A, COOPER DK. An investigation of the specificity of induced anti-pig antibodies in baboons. Xenotransplantation 2003; 10: 88.
34. LAM TT, PANIAGUA R, SHIVARAM G et al. Anti-non-Gal porcine endothelial cell antibodies in acute humoral xenograft rejection of hDAF-transgenic porcine hearts in cynomolgus monkeys. Xenotransplantation 2004; 11: 531.
35. KWIATKOWSKI P, ARTRIP JH, JOHN R et al. Induction of swine major histocompatibility complex class I molecules on porcine endothelium by tumor necrosis factor-alpha reduces lysis by human natural killer cells. Transplantation 1999; 67: 211.
36. BORENSTEIN SH, TAO KS, HU N, WEST LJ, CHAMBERLAIN JW. Induction of xenogeneic neonatal tolerance to transgenic human leukocyte antigen class I grafts. Transplantation 2004; 78: 844.
37. BACH FH, WINKLER H, FERRAN C, HANCOCK WW, ROBSON SC. Delayed xenograft rejection. Immunol Today 1996; 17: 379.
38. CASCALHO M, PLATT JL. The immunological barrier to Xenotransplantation. Immunity 2001; 14: 437.
39. SAADI S, TAKAHASHI T, HOLZKNECHT RA, PLATT JL. Pathways to acute humoral rejection. Am J Pathol 2004; 164: 1073.
40. COLLINS BJ, BLUM MG, PARKER RE et al. Thromboxane mediates pulmonary hypertension and lung inflammation during hyperacute lung rejection. J Appl Physiol 2001; 90: 2257.
41. CHITILIAN HV, LAUFER TM, STENGER K, SHEA S, AUCHINCLOSS H JR. The strength of cell-mediated xenograft rejection in the mouse is due to the CD4+ indirect response. Xenotransplantation 1998; 5: 93.
42. DORLING A, LECHLER RI. T cell-mediated xenograft rejection: specific tolerance is probably required for long term xenograft survival. Xenotransplantation 1998; 5: 234.